CN114634892A - Probiotics composition with blood fat reducing function, preparation method and equipment - Google Patents

Probiotics composition with blood fat reducing function, preparation method and equipment Download PDF

Info

Publication number
CN114634892A
CN114634892A CN202210303538.4A CN202210303538A CN114634892A CN 114634892 A CN114634892 A CN 114634892A CN 202210303538 A CN202210303538 A CN 202210303538A CN 114634892 A CN114634892 A CN 114634892A
Authority
CN
China
Prior art keywords
powder
parts
lactobacillus
screening
fixedly connected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210303538.4A
Other languages
Chinese (zh)
Inventor
皮雄娥
刘伟
费笛波
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Academy of Agricultural Sciences
Original Assignee
Zhejiang Academy of Agricultural Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Academy of Agricultural Sciences filed Critical Zhejiang Academy of Agricultural Sciences
Priority to CN202210303538.4A priority Critical patent/CN114634892A/en
Publication of CN114634892A publication Critical patent/CN114634892A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B07—SEPARATING SOLIDS FROM SOLIDS; SORTING
    • B07B—SEPARATING SOLIDS FROM SOLIDS BY SIEVING, SCREENING, SIFTING OR BY USING GAS CURRENTS; SEPARATING BY OTHER DRY METHODS APPLICABLE TO BULK MATERIAL, e.g. LOOSE ARTICLES FIT TO BE HANDLED LIKE BULK MATERIAL
    • B07B1/00—Sieving, screening, sifting, or sorting solid materials using networks, gratings, grids, or the like
    • B07B1/28—Moving screens not otherwise provided for, e.g. swinging, reciprocating, rocking, tilting or wobbling screens
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B07—SEPARATING SOLIDS FROM SOLIDS; SORTING
    • B07B—SEPARATING SOLIDS FROM SOLIDS BY SIEVING, SCREENING, SIFTING OR BY USING GAS CURRENTS; SEPARATING BY OTHER DRY METHODS APPLICABLE TO BULK MATERIAL, e.g. LOOSE ARTICLES FIT TO BE HANDLED LIKE BULK MATERIAL
    • B07B1/00—Sieving, screening, sifting, or sorting solid materials using networks, gratings, grids, or the like
    • B07B1/46—Constructional details of screens in general; Cleaning or heating of screens
    • B07B1/50—Cleaning
    • B07B1/55—Cleaning with fluid jets
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M27/00—Means for mixing, agitating or circulating fluids in the vessel
    • C12M27/16—Vibrating; Shaking; Tilting
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M33/00—Means for introduction, transport, positioning, extraction, harvesting, peeling or sampling of biological material in or from the apparatus
    • C12M33/14—Means for introduction, transport, positioning, extraction, harvesting, peeling or sampling of biological material in or from the apparatus with filters, sieves or membranes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Abstract

The invention relates to the technical field of preparation of probiotic compositions, and particularly discloses a probiotic composition with a blood fat reducing effect, a preparation method and equipment thereof, wherein the probiotic composition comprises, by weight, 20-30 parts of enterococcus faecium powder, 20-30 parts of bacillus subtilis powder, 10-22 parts of bifidobacterium powder, 10-15 parts of lactobacillus acidophilus powder, 1-10 parts of bacillus natto powder, 1-10 parts of lactobacillus casei powder, 5-10 parts of lactobacillus salivarius powder, 1-5 parts of bacillus powder, 10-15 parts of bacillus dorferi powder, 1-5 parts of bacillus subtilis powder, 10-15 parts of mucoprotein akkermanomyces powder, 10-15 parts of lactobacillus lachnospiraceae K4A136group bacteria powder and 15-25 parts of brunettus eNove bacteria powder. The invention has the characteristics of no toxic or side effect, capability of reasonably regulating intestinal flora and capability of enhancing the metabolic capability of digestive tract on the fat cholesterol.

Description

Probiotics composition with blood fat reducing function, preparation method and equipment
Technical Field
The invention relates to the technical field of preparation of probiotic compositions, in particular to a probiotic composition with a blood fat reducing effect, a preparation method and equipment.
Background
Blood lipids are a general term for neutral fats (triglycerides) and lipids (phospholipids, glycolipids, sterols, steroids) in plasma, and are widely present in the human body. They are essential substances for the basal metabolism of living cells. Generally, the main components in blood lipids are triglycerides, which are involved in energy metabolism in the human body, and cholesterol, which is mainly used for the synthesis of plasma membranes, steroid hormones, and bile acids. .
The lipids contained in plasma are collectively called blood lipids, and although the plasma lipid content accounts for a very small part of the total lipid content of the whole body, both exogenous and endogenous lipid substances need to enter the blood and move among tissues. Thus, the blood lipid content may reflect the lipid metabolism in the body. After eating high-fat meal, the lipid content of blood plasma greatly rises, but the blood plasma temporarily rises and can gradually become normal after 3-6 hours. When the blood lipid is detected, blood is usually collected 12-14 hours after meals, so that the real condition of the blood lipid level can be reliably reflected. Since elevated plasma cholesterol and triglyceride levels are associated with the development of atherosclerosis, these two items are important items for blood lipid determination.
The probiotics is also called as intestinal beneficial bacteria, and refers to nonpathogenic microorganisms which can survive in the intestinal tract, and the probiotics can help the inner wall of the intestinal tract to be free from damage, can improve the related side effects caused by taking antibiotics, such as gastroenteritis and acute diarrhea, and can also improve the symptoms of lactose intolerance. The probiotics becomes an important product for preventing and treating diseases and maintaining health of people, and has the recent effect of taking effect quickly, such as the effects of preventing and treating acute and chronic diarrhea and constipation, improving gastrointestinal functions and the like; the liver protecting tea also has obvious long-term effects, such as effects of protecting the liver and assisting in improving symptoms of liver diseases by reducing the endotoxin level of a human body, improving the nutritional status, helping the growth of liver cells, improving the immunity of the human body and the like; the probiotic bacteria can also improve the symptoms of dysbacteriosis caused by side effects in chemical, radiation and immunosuppressant treatment, such as anorexia, asthenia, and leukocyte count reduction, and improve disease resistance. A large number of researches show that the probiotics also have the function of reducing blood fat. The lactobacillus acidophilus somatic cells have the function of absorbing cholesterol in intestinal tracts, thereby reducing the absorption of the cholesterol. Scientists have discovered by scanning electron microscopy that cholesterol adheres to the cell surface of lactic acid bacteria, and is influenced by the structure and chemical properties of cell wall peptidoglycans, which contain amino acids capable of binding to cholesterol. In addition, the lactobacillus acidophilus and the bifidobacterium can inhibit the activity of a key enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) for synthesizing cholesterol, thereby reducing the synthesis amount of the cholesterol and achieving the effect of reducing blood fat.
The probiotics can improve the digestive ability of gastrointestinal strains of a human body, improve the decomposition capacity of a digestive system to fatty cholesterol, reduce blood fat and realize the effect of treating hyperlipidemia, at present, the control on the blood fat is mainly based on medicines, has toxic and side effects, has poor treatment effect, and cannot achieve the effect of reasonably regulating intestinal flora by using the probiotic composition so as to enhance the metabolic capacity of the digestive tract to the fatty cholesterol.
Therefore, the existing medicines for treating hyperlipidemia have the problems of toxic and side effects and incapability of reasonably regulating intestinal flora.
Disclosure of Invention
The invention provides a probiotic composition with the function of reducing blood fat, a preparation method and equipment for solving the technical problems of the existing treatment of hyperlipidemia, and the probiotic composition has the characteristics of no toxic or side effect, capability of reasonably regulating intestinal flora and capability of enhancing the metabolic capability of digestive tract on fat cholesterol.
The first technical scheme of the invention is as follows: the probiotic composition with the function of reducing blood fat comprises the following components in parts by weight,
20-30 parts of enterococcus faecium powder, 20-30 parts of bacillus subtilis powder, 10-22 parts of bifidobacterium powder, 10-15 parts of lactobacillus acidophilus powder, 1-10 parts of bacillus natto powder, 1-10 parts of lactobacillus casei powder, 5-10 parts of lactobacillus salivarius powder, 1-5 parts of eubacterium powder, 10-15 parts of lactobacillus ducreyi powder, 1-5 parts of paramylobacter powder, 1-5 parts of cladosporium powder, 10-15 parts of mucoprotein akkermanomyces powder, 10-15 parts of Lachnospiraceae NK4A136group bacteria powder, 15-25 parts of Braudauer bacteria powder and 10-15 parts of galactooligosaccharides.
Enterococcus faecium is a fungus in the normal flora of animal intestinal tract, and is classified as a lactic acid fungus because it can produce lactic acid. Enterococcus faecium is a probiotic, plays an important role in maintaining the ecological balance of animal intestinal flora, can inhibit the generation of ammonia of the bacteria, and can reduce the pH value of a culture medium; the reason for this is that enterococcus faecium has a small number of urease and amino acid deaminase enzymes involved in ammonia production, and has a low enzyme activity, and NH4+The activities of assimilation-related glutamate dehydrogenase, glutamate synthase and glutamine synthetase are much higher, and enterococcus faecium has a regulation and control effect on human intestinal flora;
the bacillus subtilis enters a human body, can reach the large intestine and the small intestine by 100 percent, inhibits pathogenic bacteria, promotes the growth of beneficial anaerobic bacteria, generates organic acids such as lactic acid and the like, reduces the pH value of the intestinal tract, indirectly inhibits the growth of other pathogenic bacteria, can improve the levels of immunoglobulin and antibody, enhances the cellular immunity and humoral immunity functions, improves the immunity of the population, can synthesize enzymes such as alpha-amylase, protease, lipase and cellulase, and plays a role together with digestive enzymes in an animal body (human body) in the digestive tract;
the bifidobacterium is used as a physiological beneficial bacterium, and has a plurality of important physiological functions of biological barrier, nutrition, anti-tumor, immunity enhancement, gastrointestinal tract function improvement, aging resistance and the like on human health; beneficial bacteria such as bifidobacterium, lactobacillus and the like can inhibit the growth of harmful bacteria of a human body, resist the infection of pathogenic bacteria, synthesize vitamins required by the human body, promote the absorption of the human body to mineral substances, generate organic acids such as acetic acid, propionic acid, butyric acid, lactic acid and the like to stimulate the intestinal peristalsis, promote defecation, prevent constipation, inhibit the intestinal putrefaction effect, purify the intestinal environment, decompose carcinogenic substances, stimulate the immune system of the human body, and have important functions in the aspects of improving the disease resistance and the like;
lactobacillus acidophilus: is an important microorganism in human intestinal tracts, is closely related to human health, and can play a role in health care when reaching a certain amount in vivo; the lactobacillus acidophilus can reduce the pH value in the environment through the acid metabolite of the lactobacillus acidophilus, promote the growth of anaerobic bacteria (such as bifidobacterium), simultaneously the lactobacillus acidophilus can secrete a protein adhesion promoting factor which is adhered to the cells of human intestinal mucosa to play a role of a barrier, prevent intestinal pathogenic bacteria such as escherichia coli and the like from adhering and invading the cells of the intestinal mucosa, prevent the escherichia coli and the like from overgrowing to generate a large amount of toxins, and further reduce the incidence rate of the enterogenic endotoxemia of liver cirrhosis;
b, bacillus natto: the survival rate of beneficial bacteria with acid resistance and heat resistance in four hours under gastric acid is 100 percent, and the beneficial bacteria have strong pathogenic bacteria inhibition capability, are one of various beneficial bacteria, have the best environmental tolerance and can directly reach the small intestine, can change the ecology of intestinal flora of a human body after being orally taken, help the normalization of the function of a digestive tract, ensure the defecation to be smooth and maintain the physiological environment protection in vivo; can produce acid, regulate intestinal flora and enhance the immunity response of animal cells;
lactobacillus casei: the lactobacillus casei has good acid resistance and bile resistance, can reduce plasma cholesterol, enhance the nonspecific resistance of a host to microbial pathogens, accelerate the elimination of the pathogens in the intestinal tract, treat intestinal flora disorder and enhance the intestinal permeability, thereby preventing food allergy and acute diarrhea; in addition, the lactobacillus casei can increase anti-low-density oxidized lipid antibodies and lymphocytes, obviously enhance the phagocytosis of granulocytes, regulate the immunity of a host and prevent the generation of tumors;
the lactobacillus salivarius can stimulate an immune system, stimulate Th1 type immune response which can regulate allergic immune response to balance Th2 type immune response caused by allergy, and can achieve the effect of improving allergic constitution;
eubacterium (Eubacterium) coprostanoligenes group, a true bacterium producing coprosterol, which can decompose cholesterol into unabsorbed coprosterol, and the proportion of the coprosterol can reach 50 percent along with the excretion of the coprosterol out of the body; eubacterium may be used to treat gastrointestinal and/or inflammatory disorders, including, for example, dysbiosis and/or immune-mediated inflammatory disorders, such as ulcerative colitis, crohn's disease, and other forms of Inflammatory Bowel Disease (IBD);
the Du's bacterium dubosiella can improve the abundance of beneficial microorganisms in obese mice, improve the structural disorder of mouse intestinal flora caused by high-fat diet, improve the intestinal metabolism and immunity, and reduce the occurrence of diseases such as bacterial infection and the like;
the Bacteridium belongs to Parabacteroides, is used as a microorganism for balancing intestinal tracts, and has the function of conditioning the body condition;
the cladia Alistipes plays a good role in gastric bypass surgery or other gastrointestinal obesity treatment or metabolic procedures and also has the function of improving constipation;
the Akkermansia muciniphila, Akk bacterium is a normal bacterium in human intestinal tract, is a mucinolytic bacterium, has an oval strain and is a gram-negative anaerobic bacterium, and is a representative of verrucomicrobia; the composition can effectively reduce intestinal permeability and intestinal inflammation level, further can effectively improve physical barriers, chemical barriers and immune barriers of the intestinal tract, improves or relieves the abnormal functions of the intestinal tract barriers caused by diet/metabolic diseases, and can be widely used for preparing medicines, foods or health care products for regulating the intestinal tract barrier functions;
the Lachnospiraceae NK4A136group can effectively improve the intestinal barrier function damage caused by metabolic related diseases such as obesity and the like;
the Blautia can improve the level, identity or proportion of beneficial microorganisms in a subject, enhance the responsiveness of the subject to a hypolipidemic therapy, remarkably enhance the hypolipidemic effect of a hypolipidemic drug and reduce individual differences;
galacto-oligosaccharides (GOS) are functional oligosaccharides with natural properties, and generally have a molecular structure in which 1 to 7 galactosyl groups, i.e., Gal- (Gal) n-Glc/Gal (n is 0 to 6), are linked to a galactose or glucose molecule. In nature, the milk of animals contains trace GOS, while the human breast milk contains more GOS, so that the establishment of Bifidobacterium flora in infants depends on the GOS component in the breast milk to a great extent.
The invention selects enterococcus faecium powder, bacillus subtilis powder, bifidobacterium powder, lactobacillus acidophilus powder, bacillus natto powder, lactobacillus casei powder, lactobacillus salivarius powder, bacillus eubacterium powder, lactobacillus duchenii powder, paracoccus powder, other mycobacteria powder, mucinous Ackermanobacter powder, Lachnospiraceae NK4A136group powder, Blattella powder and galactooligosaccharides which are various bacteria powder beneficial to human body, and the components are matched according to proper proportion to form the probiotic-prebiotic composition with the function of reducing blood fat, and the various components are matched and cooperated with each other, so that the original probiotics in the intestinal tract compete with each other after entering a digestive system, the probiotics in the body are propagated in large quantity, the digestive ability of the gastrointestinal strains of the human body is better improved, and the decomposition ability of the digestive system to fatty cholesterol is improved, so as to effectively reduce the fat content in the blood plasma and realize the function of reducing blood fat; by means of mutual competition among floras, the distribution of intestinal floras can be effectively adjusted, the distribution of the floras in the intestinal tract is promoted to be wider, the adjustment range of the floras to the intestinal tract is increased, the adjustment efficiency of the intestinal tract is increased, and the intestinal tract is adjusted by means of the floras, so that the absorption function of the intestinal tract to nutrient substances is improved; meanwhile, the health food has no toxic or side effect and is suitable for long-term eating.
Preferably, the composition comprises the following components in parts by weight,
22-27 parts of enterococcus faecium powder, 23-28 parts of bacillus subtilis powder, 13-20 parts of bifidobacterium powder, 12-14 parts of lactobacillus acidophilus powder, 3-7 parts of bacillus natto powder, 2-8 parts of lactobacillus casei powder, 6-9 parts of lactobacillus salivarius powder, 2-4 parts of eubacterium powder, 12-14 parts of lactobacillus ducreyi powder, 2-4 parts of paramylobacter powder, 2-4 parts of cladosporium powder, 11-14 parts of mucoprotein akkermanomyces powder, 12-14 parts of bacteria powder of Lachnospiraceae NK4A136group, 18-22 parts of blautia bacteria powder and 12-14 parts of galactooligosaccharides.
Preferably, the composition comprises the following components in parts by weight,
25 parts of enterococcus faecium powder, 25 parts of bacillus subtilis powder, 15 parts of bifidobacterium powder, 13 parts of lactobacillus acidophilus powder, 5 parts of bacillus natto powder, 5 parts of lactobacillus casei powder, 8 parts of lactobacillus salivarius powder, 3 parts of bacillus eubacterium powder, 13 parts of bacillus duchenii powder, 3 parts of paracoccus powder, 3 parts of other cladosporium powder, 12 parts of stickophilum akkermanensis powder, 13 parts of Lachnospiraceae NK4A136group bacteria powder, 20 parts of blautia bacteria powder and 13 parts of galactooligosaccharides.
The second technical scheme of the invention is as follows: the preparation method of the probiotic composition with the function of reducing blood fat comprises the following steps,
(S01) selecting a strain: selecting enterococcus faecium strains;
(S02) seed production: selecting a sterile environment, taking out the strain by using an inoculating needle, putting the strain into a triangular flask with a culture medium, sealing a bottle mouth, and putting the bottle mouth into an incubator, wherein the temperature of the incubator is 35-37 ℃, and performing static culture for 20-30 h;
(S03) sterilization: sterilizing the first fermentation tank in vacuum, then putting the first fermentation tank into a culture medium for sterilization, wherein the sterilization temperature is more than 150 ℃, the pressure in the first fermentation tank is 0.15-0.25 MPa, the sterilization lasts for 25-35 min, then the temperature in the first fermentation tank is reduced to 35-37 ℃ by cooling water, and the pressure in the first fermentation tank is reduced to 0.01-0.03 MPa;
(S04) inoculation: firstly, putting seeds in an incubator into a sterile room for sampling microscopic examination, inoculating, unscrewing a sealing cover of an inoculating port, introducing a trace amount of sterile air into a first fermentation tank, ensuring that the pressure in the tank is not zero, placing an inoculating flame ring in the inoculating port, igniting the flame ring, completely opening the inoculating cover, then placing a triangular flask above the flame ring, opening the triangular flask, pouring the seeds into the first fermentation tank, screwing the inoculating cover after the pressure is over, introducing the sterile air into the first fermentation tank, stopping when the pressure in the first fermentation tank reaches 0.05-0.09 MPa, maintaining the pressure, keeping the temperature at 35-37 ℃ and the pressure at 0.05-0.09 MPa, adjusting the stirring rotation speed to 40-60 r/min, and culturing for 20-30 h;
(S05) transplanting: the step (S02) is carried out on the second fermentation tank, then the strain in the first fermentation tank is transferred into the second fermentation tank with the culture medium through a sterilized pipeline, the temperature is kept between 35 and 37 ℃, the pressure is 0.05 to 0.09MPa, the stirring speed is adjusted to between 40 and 60r/min, the culture is carried out for 20 to 30 hours, and the density of the strain in the second fermentation tank is ensured to be 6 multiplied by 108～12×108cfu/g；
(S06) centrifugation: enabling the bacterial liquid to pass through a centrifugal machine, enabling the centrifugal machine to rotate clockwise at the rotating speed of 12000 r/min-17000 r/min, carrying out bacterial liquid separation, and taking out bacterial sludge after the bacterial liquid separation is finished;
(S07) lyophilization: placing the bacterial sludge in a plate layer of a freeze dryer, performing freeze drying operation, and automatically vacuumizing when the temperature of a cold trap of the freeze dryer is-45 ℃ to-55 ℃;
(S08) pulverizing: crushing the freeze-dried bacterial sludge to prepare enterococcus faecium bacterial powder;
(S09) preparing Bacillus subtilis powder, Bifidobacterium powder, Lactobacillus acidophilus powder, Bacillus natto powder, Lactobacillus casei powder, Lactobacillus salivarius powder, Bacillus mycoides powder, Bacillus duchensis powder, Bacillus subtilis powder, Sclerotinia bacteria powder, Ackermanomyces muciniphila powder, Lachnospiraceae NK4A136group powder and Blauteria powder: respectively repeating the steps (S02) to (S08) with bacillus subtilis, bifidobacterium, lactobacillus acidophilus, bacillus natto, lactobacillus casei, lactobacillus salivarius, eubacterium, duchenium, paracoccus, cladosporium, akmansia muciniphila, Lachnospiraceae NK4A136group bacteria and blautiella to obtain bacillus subtilis powder, bifidobacterium powder, lactobacillus acidophilus powder, bacillus natto powder, lactobacillus casei powder, lactobacillus salivarius powder, bacillus powder, duchenium powder, bacillus subtilis powder, bifidobacterium powder, another mycobacterium powder, akmansonium muciniphilus powder, Lachnospiraceae NK4A136group bacteria powder and blautiella powder;
(S10) sieving: screening enterococcus faecium powder, bacillus subtilis powder, bifidobacterium powder, lactobacillus acidophilus powder, bacillus natto powder, lactobacillus casei powder, lactobacillus salivarius powder, bacillus mycoides powder, lactobacillus duchenii powder, bacillus subtilis powder, mycobacterium powder, other-cladium powder, adhesive protein akmansonium powder, Lachnospiraceae NK4A136group powder, blautia powder and galacto-oligosaccharide by a screening device respectively;
(S11) manufacturing: under the aseptic condition, screened enterococcus faecium powder, bacillus subtilis powder, bifidobacterium powder, lactobacillus acidophilus powder, bacillus natto powder, lactobacillus casei powder, lactobacillus salivarius powder, bacillus eubacterium powder, lactobacillus dorferi powder, bacillus parabacteri powder, cladosporium powder, mucinophilic akmansonium powder, Lachnospiraceae NK4A136group bacteria powder, bulrite bacteria powder and galacto-oligosaccharide are prepared according to the weight proportion and are uniformly mixed to prepare the probiotic composition with the function of reducing blood fat.
Compared with the existing simple traditional Chinese medicine, western medicine and microecologics in the market, the traditional Chinese medicine preparation can condition the intestinal tract, substantially improve the constitution of a human body, quickly adjust the disordered intestinal tract microecologics, directly repair the damaged intestinal tract mucosa, improve the immunity of the intestinal tract, treat both symptoms and root causes, and fundamentally play roles in reducing blood fat and preventing; the probiotic composition is prepared by taking enterococcus faecium powder, bacillus subtilis powder, bifidobacterium powder, lactobacillus acidophilus powder, bacillus natto powder, lactobacillus casei powder, lactobacillus salivarius powder, bacillus mycoides powder, lactobacillus duchenius powder, paramylobacillus powder, other-cladosporium powder, akkermanophilus powder, Lachnospiraceae NK4A136group powder, blautia powder and galactooligosaccharide as raw materials, screening by a screening device, and then directly proportioning the raw materials.
More preferably, the preparation method of the probiotic composition with the function of reducing blood fat comprises the following steps,
(S01) selecting a strain: selecting enterococcus faecium strains;
(S02) seed production: selecting a sterile environment, taking out the strain by using an inoculating needle, putting the strain into a 500 ml triangular flask with a culture medium, sealing the flask opening, and putting the flask into an incubator, wherein the temperature of the incubator is 36.5 ℃, and performing static culture for 24 hours;
(S03) sterilization: sterilizing a 200L fermentation tank in vacuum, then putting the fermentation tank into a culture medium for sterilization, wherein the sterilization temperature is more than 150 ℃, the pressure in the fermentation tank is 0.2MPa, the sterilization is finished after 30min, then cooling the temperature in the fermentation tank to 36.5 ℃ by using cooling water, and the pressure in the fermentation tank is reduced to 0.02 MPa;
(S04) inoculation: firstly, putting seeds in an incubator into a sterile room for sampling microscopic examination, inoculating, unscrewing a sealing cover of an inoculating port, introducing a trace amount of sterile air into a 200L tank, ensuring that the pressure in the tank is not zero, placing an inoculating flame ring on the inoculating port, igniting the flame ring, completely opening the inoculating cover, then placing a triangular flask above the flame ring, opening the triangular flask, pouring the seeds into the tank, screwing the inoculating cover after the pressure is not zero, introducing the sterile air into the tank, stopping when the pressure in the tank reaches 0.07MPa, maintaining the pressure, keeping the temperature at 36.5 ℃, the pressure at 0.07MPa, regulating the stirring speed to 50r/min, and culturing for 24 hours;
(S05) transferring seeds: performing the step (S02) on 500L fermenter, transferring the strain in 200L fermenter to 500L fermenter with culture medium via sterilized pipeline, maintaining the temperature at 36.5 deg.C and pressure at 0.07MPa, adjusting stirring speed to 50r/min, culturing for 24 hr to ensure that the strain in 500L fermenter is in a certain volumeThe density of the strain is 6 × 108～12×108cfu/g；
(S06) centrifugation: allowing the bacterial liquid to pass through a centrifugal machine, rotating the centrifugal machine clockwise at the rotation speed of 15000r/min, separating the bacterial liquid, and taking out bacterial sludge after the separation is finished;
(S07) lyophilizing: placing the bacterial sludge in a plate layer of a freeze dryer, performing freeze drying operation, and automatically vacuumizing when the temperature of a cold trap of the freeze dryer is-50 ℃;
(S08) pulverizing: crushing the freeze-dried bacterial sludge to prepare enterococcus faecium bacterial powder;
(S09) preparing Bacillus subtilis powder, Bifidobacterium powder, Lactobacillus acidophilus powder, Bacillus natto powder, Lactobacillus casei powder, Lactobacillus salivarius powder, Bacillus mycoides powder, Bacillus duchensis powder, Bacillus subtilis powder, Sclerotinia bacteria powder, Ackermanomyces muciniphila powder, Lachnospiraceae NK4A136group powder and Blauteria powder: respectively repeating the steps (S02) to (S08) with bacillus subtilis, bifidobacterium, lactobacillus acidophilus, bacillus natto, lactobacillus casei, lactobacillus salivarius, eubacterium, duchenium, paracoccus, cladosporium, akmansia muciniphila, Lachnospiraceae NK4A136group bacteria and blautiella to obtain bacillus subtilis powder, bifidobacterium powder, lactobacillus acidophilus powder, bacillus natto powder, lactobacillus casei powder, lactobacillus salivarius powder, bacillus powder, duchenium powder, bacillus subtilis powder, bifidobacterium powder, another mycobacterium powder, akmansonium muciniphilus powder, Lachnospiraceae NK4A136group bacteria powder and blautiella powder;
(S10) sieving: screening enterococcus faecium powder, bacillus subtilis powder, bifidobacterium powder, lactobacillus acidophilus powder, bacillus natto powder, lactobacillus casei powder, lactobacillus salivarius powder, bacillus mycoides powder, lactobacillus duchenii powder, bacillus subtilis powder, mycobacterium powder, other-cladium powder, adhesive protein akmansonium powder, Lachnospiraceae NK4A136group powder, blautia powder and galacto-oligosaccharide by a screening device respectively;
(S11) manufacturing: under the aseptic condition, the screened enterococcus faecium powder, bacillus subtilis powder, bifidobacterium powder, lactobacillus acidophilus powder, bacillus natto powder, lactobacillus casei powder, lactobacillus salivarius powder, bacillus eubacterium powder, lactobacillus dorferi powder, bacillus paramterium powder, other-cladia bacteria powder, mucinophilin akmanomyces powder, Lachnospiraceae NK4A136group bacteria powder, Blattella bacteria powder and galactooligosaccharides are prepared and uniformly mixed according to the weight proportion to prepare the probiotic composition with the function of reducing blood fat.
The third technical scheme of the invention is as follows: the preparation equipment of the probiotic composition with the blood fat reducing effect comprises a screening device, wherein the screening device comprises a screening frame, the interior of the screening frame is rotatably connected with a screening hopper, the lower end of the screening hopper is fixedly connected with a screen, a driving mechanism is arranged between the screening hopper and the screening frame, the left end and the right end of the screening frame are respectively embedded with a feeding pipe, the outer end of each feeding pipe is respectively provided with a sealing cover, the inner walls of the left end and the right end of the screening frame are respectively provided with a stirring transmission mechanism, the left end and the right end of the screening hopper are respectively embedded with an air blowing mechanism, the stirring transmission mechanisms are positioned at the outer side of the air blowing mechanisms, the left end and the right end of the screening frame are respectively fixedly connected with a suspension frame, the upper end of the screening frame is fixedly connected with a ring pipe, the conduction pipes are respectively and fixedly connected between the suspension frame and the ring pipe, an extrusion supplementing mechanism is arranged between the suspension hanging frame and the conduction pipe, a material taking opening is formed in the outer end of the screening frame, and a movable door is connected to the material taking opening in a rotating mode. The invention adds raw material bacterial powder to the screen, drives the driving mechanism to drive the screening hopper to swing back and forth, on one hand, the gathered raw material bacterial powder is scattered, on the other hand, the raw material bacterial powder is rapidly screened through the swing, thereby improving the screening efficiency, in the swinging process of the screening hopper, the pressing vibration of the extrusion hemisphere and the stirring plate in the stirring transmission mechanism is transmitted to the injection cylinder to shake off the residual raw material bacterial powder on the inner wall of the screening hopper, so that the screening is more sufficient, the pressing of the stirring plate drives the air in the injection cylinder to be blown into the extrusion supplementing mechanism, so that the extrusion supplementing mechanism supplements the cooling gel of the annular pipe through the storage balloon and the conduction pipe under the action of expansion and extrusion, on the other hand, the stable heat dissipation is ensured, and on the other hand, the cooling gel flows to enhance the heat dissipation effect, avoid the high temperature to cause the interference to the screening of raw materials fungus powder, reject the mechanism of blowing simultaneously with the help of the inflation of extrusion complementary mechanism and blow off the air in the injection section of thick bamboo, blow off accumulational raw materials fungus powder on the screen cloth, make it difficult emergence block up, reinforcing screening effect, then get the material with the help of getting material mouth and dodge gate to the raw materials fungus powder after the screening fast, the reinforcing is got the material effect.
Preferably, the driving mechanism comprises a swing motor installed at the top end in the screening frame, a swing joint rod is fixedly connected between the inner walls of the screening buckets, the upper ends of the swing joint rod are flush with the upper ends of the screening buckets, and the power output end of the swing motor is fixedly connected with the upper ends of the swing joint rod. The swing motor drives the screening hopper and the screen to swing back and forth by means of the swing connecting rod, so that raw material bacteria powder gathered on the screen can be scattered, and the raw material bacteria powder can be fully and comprehensively screened under the swing action.
Preferably, the stirring transfer mechanism comprises a pair of connecting straight plates fixedly connected with the inner wall of the screening frame, a stirring plate is rotatably connected between the pair of connecting straight plates, an injection cylinder is embedded in the outer end of the screening hopper, an extrusion hemisphere is fixedly connected to the outer end of the injection cylinder, and the extrusion hemisphere is in contact with the stirring plate. Realize making a round trip to extrude the hemisphere and extrude the stirring board and move at the screening fill swing in-process, make both produce the vibration to on will vibrating through spraying a section of thick bamboo, shake to remaining raw materials fungus powder on the screening fill inner wall and fall, make its screening more abundant.
Preferably, the extrusion supplementing mechanism comprises an air injection cylinder embedded on the outer end of the screening frame, a piston is slidably connected inside the air injection cylinder, a press rod is fixedly connected to the outer end of the piston, a through hole is drilled in the inner wall of the air injection cylinder, the press rod penetrates through the through hole to be rotatably connected with the dial plate, a magnetic isolation capsule is fixedly connected between the suspension hanging frame and the screening frame, a magnet block is arranged inside the magnetic isolation capsule, magnetic isolation powder is filled inside the magnetic isolation capsule, the air injection cylinder is fixedly connected with the magnetic isolation capsule, the air injection cylinder is communicated with the inside of the magnetic isolation capsule, a breathable spacer is fixedly connected to the inner wall of the air injection cylinder, a pushing block is fixedly connected to the upper end of the magnetic isolation capsule, a movable block is slidably connected between the suspension hanging frame and the screening frame, the movable block is fixedly connected with the pushing block, and a storage balloon is fixedly connected to the top end of the suspension hanging frame, the storage sacculus with link up the movable block fixed connection, the conduction tube runs through the upper end of suspension frame, conduction tube and storage sacculus fixed connection, the conduction tube is linked together with the inside of storage sacculus, conduction tube and annular tube all is equipped with the cooling gel, the inside fixedly connected with release valve of conduction tube, the initial condition of release valve is the state of drawing in, the upper end of screening frame is equipped with the diamond powder layer. When the stirring plate is extruded to move, the pressing rod pushes the piston to blow air in the air injection cylinder into the magnet isolating bag body, so that the air is expanded upwards to drive the pushing block and the connecting movable block to move upwards, cooling gel in the material storage bag is extruded to be supplemented into the annular pipe through the conduction pipe, cooling gel consumed after gasification and heat absorption in the annular pipe can be supplemented, stable heat dissipation of the gel is guaranteed, meanwhile, the cooling gel flows by means of blowing supplement of the gel, and the heat dissipation and cooling effects of the gel are enhanced.
Preferably, the magnetism-insulating powder is made of Fe-Ni alloy material, the Ni content in the magnetism-insulating powder is 80%, the outer end of the air-permeable partition is provided with a plurality of air-permeable micropores which are uniformly distributed, and the pore diameter of each air-permeable micropore is smaller than the particle size of the magnetism-insulating powder. The magnetism-insulating powder made of Fe-Ni alloy material can effectively shield the magnetic influence of the magnet blocks in a dense state, the ventilation micropores are formed, the pore diameter of the ventilation micropores is smaller than the grain diameter of the magnetism-insulating powder, and the magnetism-insulating powder is not easy to leak outwards on the basis of realizing air circulation.
As preferred, the outer end that promotes the piece is the drop form setting, link up the equal fixedly connected with slider in both ends about the movable block, the inner wall of suspension connection hanging frame and the outer end of screening frame have all been dug the spout, slider and spout sliding connection. Through the setting of slider and spout, make the motion that links up the movable block more smooth and easy convenient, reduce the friction influence.
Preferably, the release valve is in a gathered state when not compressed, and the release valve is in an open state when compressed. The cooling gel is not easy to flow outwards through the release valve in the gathering state, the blocking effect is achieved, the gathering state in the opening state after the extrusion effect can achieve flowing of the cooling gel, and the cooling gel is convenient to supplement.
Preferably, the blowing mechanism comprises an elastic extrusion film fixedly connected with the inner wall of the injection cylinder, the outer end of the elastic extrusion film is fixedly connected with a magnet piece, one end, close to the magnet piece, of the magnet piece is repelled, a plurality of uniformly distributed air injection holes are formed in the outer end of the injection cylinder, and the inner wall of each air injection hole is fixedly connected with a movable injection bottle nozzle. After the magnet insulating utricule inflation, the magnetism insulating powder diffusion, the magnetic screen of cancellation magnet piece, the air that repelling magnet piece drove the crooked extrusion of elastic extrusion membrane and sprayed in the section of thick bamboo spouts through the sports type injection bottle mouth, blows off the raw materials fungus powder of piling up on the screen cloth, makes it difficult emergence jam, reinforcing screening effect.
The invention has the following beneficial effects:
(1) the probiotic composition with the blood fat reducing function is formed by matching a plurality of bacteria powders which are beneficial to human bodies, such as enterococcus faecium powder, bacillus subtilis powder, bifidobacterium powder, lactobacillus acidophilus powder, bacillus natto powder, lactobacillus casei powder, lactobacillus salivarius powder, bacillus fungal powder, lactobacillus bacterial powder, lactobacillus plantarum NK4A136group, blautia bacterial powder and galactooligosaccharides according to proper proportion, the components are matched and then mutually cooperated after entering a digestive system, the original probiotics in the intestinal tract are mutually competed, so that the mass propagation of the probiotics in the human body is realized, the digestive capacity of the gastrointestinal bacteria of the human body is better improved, the decomposition capacity of the digestive system on fatty cholesterol is improved, and the fat content in blood plasma is effectively reduced, the function of reducing blood fat is realized;
(2) by means of mutual competition among floras, the distribution of intestinal floras can be effectively adjusted, the distribution of the floras in the intestinal tract is promoted to be wider, the adjustment range of the floras to the intestinal tract is increased, the adjustment efficiency of the intestinal tract is increased, and the intestinal tract is adjusted by means of the floras, so that the absorption function of the intestinal tract to nutrient substances is improved; meanwhile, the health food has no toxic or side effect and is suitable for long-term eating;
(3) compared with the existing pure traditional Chinese medicines, western medicines and microecologics in the market, the traditional Chinese medicine preparation can condition the intestinal tract to essentially improve the physique of a human body, can quickly adjust the disordered intestinal tract microecological system, directly repair the damaged intestinal mucosa, improve the intestinal immunity, treat both symptoms and root causes, and fundamentally play roles in reducing blood fat and preventing;
(4) the probiotic composition is prepared by taking enterococcus faecium powder, bacillus subtilis powder, bifidobacterium powder, lactobacillus acidophilus powder, bacillus natto powder, lactobacillus casei powder, lactobacillus salivarius powder, bacillus eubacterium powder, lactobacillus duchenius powder, lactobacillus powder, other-cladium powder, mucinophilus akkermanensis powder, Lachnospiraceae NK4A136group powder, blautia powder and galacto-oligosaccharide as raw materials, screening by a screening device, and then directly proportioning and feeding the raw materials according to the scientific proportioning by weight, and the preparation process is simple;
(5) raw material bacterial powder is added onto the screen mesh, the driving mechanism drives the screening hopper to swing back and forth, on one hand, the gathered raw material bacterial powder is scattered, on the other hand, the raw material bacterial powder is rapidly screened through swinging, so that the screening efficiency is improved, in the swinging process of the screening hopper, the pressing vibration of the extrusion hemisphere and the stirring plate in the stirring transmission mechanism is transmitted to the injection cylinder to shake and fall the residual raw material bacterial powder on the inner wall of the screening hopper, so that the screening is more sufficient, the pressing of the stirring plate drives the air in the injection cylinder to be blown into the extrusion supplementing mechanism, so that the extrusion supplementing mechanism supplements the cooling gel of the annular pipe through the storage balloon and the conduction pipe under the action of expansion and extrusion, on the other hand, the stable heat dissipation is ensured, and on the other hand, the cooling gel flows to enhance the heat dissipation effect, avoid the high temperature to cause the interference to the screening of raw materials fungus powder, reject the mechanism of blowing simultaneously with the help of the inflation of extrusion complementary mechanism and blow off the air in the injection section of thick bamboo, blow off accumulational raw materials fungus powder on the screen cloth, make it difficult emergence block up, reinforcing screening effect, then get the material with the help of getting material mouth and dodge gate to the raw materials fungus powder after the screening fast, the reinforcing is got the material effect.
Drawings
FIG. 1 is a schematic perspective view of the present invention;
FIG. 2 is a schematic overall sectional structure of the present invention;
FIG. 3 is a schematic perspective view of a screening hopper according to the present invention;
FIG. 4 is a schematic perspective view of the toggle transfer mechanisms of the present invention;
FIG. 5 is a schematic view of a partial cross-sectional structure of the supplemental extrusion mechanism of the present invention;
FIG. 6 is a schematic sectional view of the air injection mechanism according to the present invention;
FIG. 7 is a statistical chart of blood lipids of a mouse at week 7 after administration in the animal experiment of the present invention;
FIG. 8 is a statistical chart of blood lipids at week 8 after administration to mice in the animal experiment of the present invention;
FIG. 9 is a graph of the percentage of the level of the intestinal flora versus the abundance in the animal experimental group of the present invention.
The labels in the figures are: 100-screening frame; 200-a drive mechanism; 201-a swing motor; 202-swing joint bar; 300-a screening hopper; 400-a feed pipe; 500-screen mesh; 600-a movable door; 700-hanging a hanging frame; 800-toggle transfer mechanism; 801-connecting straight plates; 802-toggle plate; 803-an injection cartridge; 804-extruding the hemisphere; 900-extrusion replenishment mechanism; 901-gas filling cylinder; 902-a piston; 903-pressing rod; 904-breathable barrier; 905-magnetic insulation capsule body; 906-magnet block; 907-pushing block; 908-engaging the movable block; 909-storage balloon; 9010-release valve; 1000-a blowing mechanism; 10001-elastic extruded film; 10002-magnet pieces; 10003-sports spray tip; 1100-ring pipe; 1200-conducting tube.
Detailed Description
The present invention will be further described with reference to the following examples and drawings, but the invention is not limited thereto.
In the description of the present invention, it should be noted that the terms "upper", "lower", "inner", "outer", "top/bottom", etc. indicate orientations or positional relationships based on orientations or positional relationships shown in the drawings, which are merely for convenience of description and simplification of description, but do not indicate or imply that the device or element referred to must have a specific orientation, be constructed and operated in a specific orientation, and thus, should not be construed as limiting the present invention. Furthermore, the terms "first" and "second" are used for descriptive purposes only and are not to be construed as indicating or implying relative importance.
In the description of the present invention, it should be noted that, unless otherwise explicitly specified or limited, the terms "mounted," "disposed," "sleeved/connected," "connected," and the like are to be construed broadly, e.g., "connected," which may be fixedly connected, detachably connected, or integrally connected; can be mechanically or electrically connected; they may be connected directly or indirectly through intervening media, or they may be interconnected between two elements. The specific meanings of the above terms in the present invention can be understood in specific cases to those skilled in the art.
The probiotic composition with the function of reducing blood fat comprises the following components in parts by weight,
20-30 parts of enterococcus faecium powder, 20-30 parts of bacillus subtilis powder, 10-22 parts of bifidobacterium powder, 10-15 parts of lactobacillus acidophilus powder, 1-10 parts of bacillus natto powder, 1-10 parts of lactobacillus casei powder, 5-10 parts of lactobacillus salivarius powder, 1-5 parts of eubacterium powder, 10-15 parts of lactobacillus ducreyi powder, 1-5 parts of paramylobacter powder, 1-5 parts of cladosporium powder, 10-15 parts of mucoprotein akkermanomyces powder, 10-15 parts of Lachnospiraceae NK4A136group bacteria powder, 15-25 parts of Braudauer bacteria powder and 10-15 parts of galactooligosaccharides.
The probiotic composition with the function of reducing blood fat comprises the following components in parts by weight,
22-27 parts of enterococcus faecium powder, 23-28 parts of bacillus subtilis powder, 13-20 parts of bifidobacterium powder, 12-14 parts of lactobacillus acidophilus powder, 3-7 parts of bacillus natto powder, 2-8 parts of lactobacillus casei powder, 6-9 parts of lactobacillus salivarius powder, 2-4 parts of eubacterium powder, 12-14 parts of lactobacillus ducreyi powder, 2-4 parts of paramylobacter powder, 2-4 parts of cladosporium powder, 11-14 parts of mucoprotein akkermanomyces powder, 12-14 parts of bacteria powder of Lachnospiraceae NK4A136group, 18-22 parts of blautia bacteria powder and 12-14 parts of galactooligosaccharides.
The preparation method of the probiotic composition with the function of reducing blood fat comprises the following steps,
(S01) selecting a strain: selecting enterococcus faecium strains;
(S02) seed production: selecting a sterile environment, taking out the strain by using an inoculating needle, putting the strain into a triangular flask with a culture medium, sealing a bottle mouth, and putting the bottle mouth into an incubator, wherein the temperature of the incubator is 35-37 ℃, and performing static culture for 20-30 h;
(S03) sterilization: sterilizing the first fermentation tank in vacuum, then putting the first fermentation tank into a culture medium for sterilization, wherein the sterilization temperature is more than 150 ℃, the pressure in the first fermentation tank is 0.15-0.25 MPa, the sterilization lasts for 25-35 min, then the temperature in the first fermentation tank is reduced to 35-37 ℃ by cooling water, and the pressure in the first fermentation tank is reduced to 0.01-0.03 MPa;
(S04) inoculation: firstly, putting seeds in an incubator into a sterile room for sampling microscopic examination, inoculating, unscrewing a sealing cover of an inoculating port, introducing a trace amount of sterile air into a first fermentation tank, ensuring that the pressure in the tank is not zero, placing an inoculating flame ring in the inoculating port, igniting the flame ring, completely opening the inoculating cover, then placing a triangular flask above the flame ring, opening the triangular flask, pouring the seeds into the first fermentation tank, screwing the inoculating cover after the pressure is over, introducing the sterile air into the first fermentation tank, stopping when the pressure in the first fermentation tank reaches 0.05-0.09 MPa, maintaining the pressure, keeping the temperature at 35-37 ℃ and the pressure at 0.05-0.09 MPa, adjusting the stirring rotation speed to 40-60 r/min, and culturing for 20-30 h;
(S05) transplanting: the step (S02) is carried out on the second fermentation tank, then the strain in the first fermentation tank is transferred into the second fermentation tank with the culture medium through a sterilized pipeline, the temperature is kept between 35 and 37 ℃, the pressure is 0.05 to 0.09MPa, the stirring speed is adjusted to between 40 and 60r/min, the culture is carried out for 20 to 30 hours, and the density of the strain in the second fermentation tank is ensured to be 6 multiplied by 108～12×108cfu/g；
(S06) centrifugation: allowing the bacterial liquid to pass through a centrifugal machine, rotating the centrifugal machine clockwise at the rotating speed of 12000 r/min-17000 r/min, separating the bacterial liquid, and taking out bacterial sludge after the separation is finished;
(S07) lyophilization: placing the bacterial sludge in a plate layer of a freeze dryer, performing freeze drying operation, and automatically vacuumizing when the temperature of a cold trap of the freeze dryer is-45 ℃ to-55 ℃;
(S08) pulverizing: crushing the freeze-dried bacterial sludge to prepare enterococcus faecium bacterial powder;
(S09) preparing a powder of a Bacillus subtilis bacterium, a powder of a Bifidobacterium bacterium, a powder of a Lactobacillus acidophilus bacterium, a powder of a Bacillus natto bacterium, a powder of a Lactobacillus casei bacterium, a powder of a Lactobacillus salivarius bacterium, a powder of a Bacillus bacterium, a powder of a Mycobacterium bacterium, a powder of an Ackermanobacter muciniphila, a powder of a Spirochaeta Lachnospiraceae NK4A136group bacterium, and a powder of a Blauteria bacterium: respectively repeating the steps (S02) to (S08) with bacillus subtilis, bifidobacterium, lactobacillus acidophilus, bacillus natto, lactobacillus casei, lactobacillus salivarius, eubacterium, duchenium, paracoccus, cladosporium, akmansia muciniphila, Lachnospiraceae NK4A136group bacteria and blautiella to obtain bacillus subtilis powder, bifidobacterium powder, lactobacillus acidophilus powder, bacillus natto powder, lactobacillus casei powder, lactobacillus salivarius powder, bacillus powder, duchenium powder, bacillus subtilis powder, bifidobacterium powder, another mycobacterium powder, akmansonium muciniphilus powder, Lachnospiraceae NK4A136group bacteria powder and blautiella powder;
(S10) sieving: screening enterococcus faecium powder, bacillus subtilis powder, bifidobacterium powder, lactobacillus acidophilus powder, bacillus natto powder, lactobacillus casei powder, lactobacillus salivarius powder, bacillus mycoides powder, lactobacillus duchenii powder, bacillus subtilis powder, mycobacterium powder, other-cladium powder, adhesive protein akmansonium powder, Lachnospiraceae NK4A136group powder, blautia powder and galacto-oligosaccharide by a screening device respectively;
(S11) manufacturing: under the aseptic condition, the screened enterococcus faecium powder, bacillus subtilis powder, bifidobacterium powder, lactobacillus acidophilus powder, bacillus natto powder, lactobacillus casei powder, lactobacillus salivarius powder, bacillus eubacterium powder, lactobacillus dorferi powder, bacillus paramterium powder, other-cladia bacteria powder, mucinophilin akmanomyces powder, Lachnospiraceae NK4A136group bacteria powder, Blattella bacteria powder and galactooligosaccharides are prepared and uniformly mixed according to the weight proportion to prepare the probiotic composition with the function of reducing blood fat.
The first fermenter is a 200-liter fermenter; the second fermentor was a 500 liter fermentor.
The preparation method of the probiotic composition with the function of reducing blood fat comprises the following steps,
(S01) selecting a strain: selecting enterococcus faecium strains;
(S02) seed production: selecting a sterile environment, taking out the strain by using an inoculating needle, putting the strain into a 500 ml triangular flask with a culture medium, sealing the flask opening, and putting the flask into an incubator, wherein the temperature of the incubator is 36.5 ℃, and performing static culture for 24 hours;
(S03) sterilization: sterilizing a 200L fermentation tank in vacuum, then putting the fermentation tank into a culture medium for sterilization, wherein the sterilization temperature is more than 150 ℃, the pressure in the fermentation tank is 0.2MPa, the sterilization is finished after 30min, then cooling the temperature in the fermentation tank to 36.5 ℃ by using cooling water, and the pressure in the fermentation tank is reduced to 0.02 MPa;
(S04) inoculation: firstly, putting seeds in an incubator into a sterile room for sampling microscopic examination, inoculating, unscrewing a sealing cover of an inoculating port, introducing a trace amount of sterile air into a 200L tank, ensuring that the pressure in the tank is not zero, placing an inoculating flame ring on the inoculating port, igniting the flame ring, completely opening the inoculating cover, then placing a triangular flask above the flame ring, opening the triangular flask, pouring the seeds into the tank, screwing the inoculating cover after the pressure is not zero, introducing the sterile air into the tank, stopping when the pressure in the tank reaches 0.07MPa, maintaining the pressure, keeping the temperature at 36.5 ℃, the pressure at 0.07MPa, regulating the stirring speed to 50r/min, and culturing for 24 hours;
(S05) transplanting: performing the step (S02) on 500L fermenter, transferring the strain in 200L fermenter to 500L fermenter with culture medium via sterilized pipeline, maintaining the temperature at 36.5 deg.C and pressure at 0.07MPa, stirring and rotating at a speed of 50r/min, culturing for 24 hr to ensure the strain density in 500L fermenter to be 6 × 108～12×108cfu/g；
(S06) centrifugation: allowing the bacterial liquid to pass through a centrifugal machine, rotating the centrifugal machine clockwise at the rotation speed of 15000r/min, separating the bacterial liquid, and taking out bacterial sludge after the separation is finished;
(S07) lyophilization: placing the bacterial sludge in a plate layer of a freeze dryer, performing freeze drying operation, and automatically vacuumizing when the temperature of a cold trap of the freeze dryer is-50 ℃;
(S08) pulverizing: crushing the freeze-dried bacterial sludge to prepare enterococcus faecium bacterial powder;
(S09) preparing Bacillus subtilis powder, Bifidobacterium powder, Lactobacillus acidophilus powder, Bacillus natto powder, Lactobacillus casei powder, Lactobacillus salivarius powder, Bacillus mycoides powder, Bacillus duchensis powder, Bacillus subtilis powder, Sclerotinia bacteria powder, Ackermanomyces muciniphila powder, Lachnospiraceae NK4A136group powder and Blauteria powder: respectively repeating the steps (S02) to (S08) with bacillus subtilis, bifidobacterium, lactobacillus acidophilus, bacillus natto, lactobacillus casei, lactobacillus salivarius, eubacterium, duchenium, paracoccus, cladosporium, akmansia muciniphila, Lachnospiraceae NK4A136group bacteria and blautiella to obtain bacillus subtilis powder, bifidobacterium powder, lactobacillus acidophilus powder, bacillus natto powder, lactobacillus casei powder, lactobacillus salivarius powder, bacillus powder, duchenium powder, bacillus subtilis powder, bifidobacterium powder, another mycobacterium powder, akmansonium muciniphilus powder, Lachnospiraceae NK4A136group bacteria powder and blautiella powder;
(S10) sieving: screening enterococcus faecium powder, bacillus subtilis powder, bifidobacterium powder, lactobacillus acidophilus powder, bacillus natto powder, lactobacillus casei powder, lactobacillus salivarius powder, bacillus mycoides powder, lactobacillus duchenii powder, bacillus subtilis powder, mycobacterium powder, other-cladium powder, adhesive protein akmansonium powder, Lachnospiraceae NK4A136group powder, blautia powder and galacto-oligosaccharide by a screening device respectively;
(S11) manufacturing: under the aseptic condition, the screened enterococcus faecium powder, bacillus subtilis powder, bifidobacterium powder, lactobacillus acidophilus powder, bacillus natto powder, lactobacillus casei powder, lactobacillus salivarius powder, bacillus eubacterium powder, lactobacillus dorferi powder, bacillus paramterium powder, other-cladia bacteria powder, mucinophilin akmanomyces powder, Lachnospiraceae NK4A136group bacteria powder, Blattella bacteria powder and galactooligosaccharides are prepared and uniformly mixed according to the weight proportion to prepare the probiotic composition with the function of reducing blood fat.
A preparation device of probiotic composition with blood fat reducing effect comprises a screening device shown in figures 1 and 2, the screening device comprises a screening frame 100, the inside of the screening frame 100 is rotatably connected with a screening hopper 300 shown in figure 4, the lower end of the screening hopper 300 is fixedly connected with a screen 500, a driving mechanism 200 is arranged between the screening hopper 300 and the screening frame 100, the left end and the right end of the screening frame 100 are respectively embedded with a feeding pipe 400, the outer end of the feeding pipe 400 is respectively provided with a sealing cover, the inner walls of the left end and the right end of the screening frame 100 are respectively provided with a stirring transmission mechanism 800, the left end and the right end of the screening hopper 300 are respectively embedded with an air blowing mechanism 1000, the stirring transmission mechanisms 800 are positioned at the outer side of the air blowing mechanism 1000, the left end and the right end of the screening frame 100 are respectively fixedly connected with a suspension frame 700 shown in figure 5, the upper end of the screening frame 100 is fixedly connected with a ring pipe 1100, and a conduction pipe 1200 is respectively fixedly connected between the suspension frame 700 and the ring pipe 1100, the conduction pipe 1200 is respectively communicated with the suspension frame 700 and the interior of the annular pipe 1100, an extrusion supplementing mechanism 900 is arranged between the suspension frame 700 and the conduction pipe 1200, a material taking opening is drilled at the outer end of the screening frame 100, and a movable door 600 is rotatably connected in the material taking opening.
The driving mechanism 200 comprises a swing motor 201 installed at the top end in the screening frame 100, a swing joint rod 202 is fixedly connected between the inner walls of the screening hoppers 300, the upper ends of the swing joint rod 202 are flush with the upper ends of the screening hoppers 300, and the power output end of the swing motor 201 is fixedly connected with the upper ends of the swing joint rod 202.
The toggle transmission mechanism 800 comprises a pair of straight connecting plates 801 as shown in fig. 3 fixedly connected with the inner wall of the screening frame 100, a toggle plate 802 rotatably connected between the pair of straight connecting plates 801, an injection cylinder 803 as shown in fig. 6 embedded in the outer end of the screening hopper 300, an extrusion hemisphere 804 fixedly connected with the outer end of the injection cylinder 803, and the extrusion hemisphere 804 in contact with the toggle plate 802.
The extrusion supplementing mechanism 900 comprises an air injection cylinder 901 embedded on the outer end of the screening frame 100, a piston 902 is connected inside the air injection cylinder 901 in a sliding manner, a press rod 903 is fixedly connected on the outer end of the piston 902, a through hole is cut on the inner wall of the air injection cylinder 901, the press rod 903 passes through the through hole to be connected with the dial plate 802 in a rotating manner, a magnetism insulation capsule 905 is fixedly connected between the suspension frame 700 and the screening frame 100, a magnet block 906 is arranged inside the magnetism insulation capsule 905, magnetism insulation powder is filled inside the magnetism insulation capsule 905, the air injection cylinder 901 is fixedly connected with the magnetism insulation capsule 905, the air injection cylinder 901 is communicated with the inside of the magnetism insulation capsule 905, an air permeable spacer 904 is fixedly connected on the inner wall of the air injection cylinder 901, a push block 907 is fixedly connected on the upper end of the magnetism insulation capsule 905, a connecting movable block 908 is connected between the suspension frame 700 and the screening frame 100 in a sliding manner, the connecting movable block 908 is fixedly connected with the push block 907, a storage balloon 909 is fixedly connected on the top end of the suspension frame 700, the storage balloon 909 is fixedly connected with the connecting movable block 908, the conducting tube 1200 penetrates through the upper end of the suspension frame 700, the conducting tube 1200 is fixedly connected with the storage balloon 909, the conducting tube 1200 is communicated with the inside of the storage balloon 909, cooling gel is arranged inside the storage balloon 909, the conducting tube 1200 and the annular tube 1100, the release valve 9010 is fixedly connected inside the conducting tube 1200, the initial state of the release valve 9010 is a furled state, and a diamond powder layer is arranged at the upper end of the screening frame 100.
The magnetic isolation powder is made of Fe-Ni alloy material, the content of Ni in the magnetic isolation powder is 80%, the outer end of the air-permeable partition 904 is provided with a plurality of air-permeable micropores which are uniformly distributed, and the pore diameter of the air-permeable micropores is smaller than the particle diameter of the magnetic isolation powder.
The outer end of the pushing block 907 is arranged in a water-drop shape, the left end and the right end of the connecting movable block 908 are fixedly connected with sliding blocks, sliding grooves are formed in the inner wall of the suspension hanging frame 700 and the outer end of the screening frame 100, and the sliding blocks are in sliding connection with the sliding grooves.
The release valve 9010 is in a gathered state when not pressed, and the release valve 9010 is in an open state after being pressed.
The blowing mechanism 1000 comprises an elastic extrusion film 10001 fixedly connected with the inner wall of the jetting cylinder 803, the outer end of the elastic extrusion film 10001 is fixedly connected with a magnet sheet 10002, one end of the magnet block 906, which is close to the magnet sheet 10002, is repelled, the outer end of the jetting cylinder 803 is provided with a plurality of evenly distributed air injection holes, and the inner wall of each air injection hole is fixedly connected with a moving type jetting bottle nozzle 10003.
The preparation equipment of the probiotic composition with the blood fat reducing effect comprises a screening device, the screening device comprises a screening frame 100, the interior of the screening frame 100 is rotatably connected with a screening hopper 300, the lower end of the screening hopper 300 is fixedly connected with a screen 500, a driving mechanism 200 is arranged between the screening hopper 300 and the screening frame 100, two feeding pipes 400 are respectively embedded at the left end and the right end of the screening frame 100, the outer ends of the two feeding pipes 400 are respectively provided with a sealing cover, the inner walls of the left end and the right end of the screening frame 100 are respectively provided with a stirring transmission mechanism 800, the left end and the right end of the screening hopper 300 are respectively embedded with an air blowing mechanism 1000, the stirring transmission mechanism 800 is positioned at the outer side of the air blowing mechanism 1000, the left end and the right end of the screening frame 100 are respectively fixedly connected with a suspension hanging frame 700, the upper end of the screening frame 100 is fixedly connected with a ring pipe 1100, a conduction pipe 1200 is respectively and fixedly connected between the two suspension hanging frames 700 and the ring pipe 1100, an extrusion supplementing mechanism 900 is arranged between the suspension frame 700 and the conduction pipe 1200, a material taking port is drilled at the outer end of the screening frame 100, and two movable doors 600 are rotationally connected in the material taking port, in the scheme, raw material bacterial powder is added on the screen cloth 500, the driving and driving mechanism 200 drives the screening hopper 300 to swing back and forth, on one hand, the gathered raw material bacterial powder is scattered, on the other hand, the raw material bacterial powder is rapidly screened through swinging, so that the screening efficiency is improved, in the swinging process of the screening hopper 300, the pressing vibration of the extrusion hemisphere 804 and the stirring plate 802 in the stirring and transmitting mechanism 800 is transmitted to the injection cylinder 803 to shake off the residual raw material bacterial powder on the inner wall of the screening hopper 300, so that the screening is more sufficient, the air in the injection cylinder 901 is driven by the pressing of the stirring plate 802 to be blown into the extrusion supplementing mechanism 900, so that the extrusion supplementing mechanism 900 supplements the cooling gel of the annular pipe 1100 through the storage balloon 909 and the conduction pipe 1200 under the expansion extrusion effect, on the one hand, supply the consumption of cooling gel, guarantee its stable heat dissipation, on the other hand, the drum-in through cooling gel is supplied, make it take place to flow and strengthen its radiating effect, avoid the high temperature to cause the interference to the screening of raw materials fungus powder, reject the air in the mechanism 1000 blows out the injection section of thick bamboo 803 with the help of the inflation of extrusion complementary unit 900 simultaneously, blow off accumulational raw materials fungus powder on the screen cloth 500, make it difficult for taking place to block up, reinforcing screening effect, then get the material with the help of getting material mouth and dodge gate 600 and carry out the material fast to the raw materials fungus powder after the screening, the reinforcing is got the material effect.
The driving mechanism 200 comprises a swing motor 201 installed at the top end in the screening frame 100, a swing joint rod 202 is fixedly connected between the inner walls of the screening hopper 300, the upper end of the swing joint rod 202 is flush with the upper end of the screening hopper 300, the power output end of the swing motor 201 is fixedly connected with the upper end of the swing joint rod 202, the screening hopper 300 and the screen cloth 500 are driven by the swing motor 201 through the swing joint rod 202 to swing back and forth, raw material bacterial powder gathered on the screen cloth 500 can be scattered, and the raw material bacterial powder is fully and comprehensively screened under the swing action.
Toggle transfer mechanism 800 includes the straight board 801 of being connected with screening frame 100 inner wall fixed connection's a pair of, it is connected with stirring board 802 to rotate between the straight board 801 of being connected to a pair of, the outer end of screening fill 300 inlays and is equipped with two and sprays a section of thick bamboo 803, the outer end fixedly connected with extrusion hemisphere 804 of a section of thick bamboo 803, extrusion hemisphere 804 contacts with stirring board 802, realize in the swing in-process of screening fill 300, extrusion hemisphere 804 makes a round trip to extrude stirring board 802 and moves, make both produce the vibration, and will vibrate on spouting a section of thick bamboo 803, shake and fall to remaining raw materials fungus powder on the screening fill 300 inner wall, make its screening more abundant.
The extrusion supplementing mechanism 900 comprises an air injection cylinder 901 embedded on the outer end of the screening frame 100, a piston 902 is connected inside the air injection cylinder 901 in a sliding manner, a press rod 903 is fixedly connected on the outer end of the piston 902, a through hole is cut on the inner wall of the air injection cylinder 901, the press rod 903 penetrates through the through hole to be connected with a poking plate 802 in a rotating manner, a magnetism-insulating capsule 905 is fixedly connected between the suspension frame 700 and the screening frame 100, a magnet block 906 is arranged inside the magnetism-insulating capsule 905, magnetism-insulating powder is filled inside the magnetism-insulating capsule 905, the air injection cylinder 901 is fixedly connected with the magnetism-insulating capsule 905 and communicated with the inside of the magnetism-insulating capsule, a ventilating spacer 904 is fixedly connected on the inner wall of the air injection cylinder 901, a pushing block 907 is fixedly connected on the upper end of the magnetism-insulating capsule 905, a connecting movable block 908 is connected between the suspension frame 700 and the screening frame 100 in a sliding manner, the connecting movable block 908 is fixedly connected with the pushing block 907, a storage balloon 909 is fixedly connected on the inner top end of the suspension frame 700, the storage balloon 909 is fixedly connected with the connecting movable block 908, the conducting tube 1200 penetrates through the upper end of the suspension frame 700, the conducting tube 1200 is fixedly connected with the storage balloon 909 and is communicated with the inside of the storage balloon 909, cooling gel is arranged inside the storage balloon 909, the conducting tube 1200 and the annular tube 1100, the inside of the conducting tube 1200 is fixedly connected with the release valve 9010, the initial state of the release valve 9010 is a folded state, the upper end of the screening frame 100 is provided with a diamond powder layer, when the poking plate 802 is extruded to move, the push rod 903 pushes the piston 902 to blow air in the air injection tube 901 into the magnetism-insulating bag 905, so that the release valve is expanded upwards to drive the push block 907 and the connecting movable block 908 to move upwards, the cooling gel in the storage balloon 909 is squeezed to supplement the annular tube 1100 through the conducting tube 1200, the cooling gel consumed after gasification and heat absorption in the annular tube 1100 can be supplemented, and stable heat dissipation of the cooling gel is ensured, meanwhile, the cooling gel flows by virtue of the bubbling supplement of the gel, so that the heat dissipation and cooling effects of the gel are enhanced.
The magnetism-insulating powder is made of Fe-Ni alloy materials, the Ni content in the magnetism-insulating powder is 80%, the outer end of the ventilation spacer 904 is provided with a plurality of ventilation micropores which are uniformly distributed, the aperture of each ventilation micropore is smaller than the particle size of the magnetism-insulating powder, the magnetism influence of the magnet block 906 can be effectively shielded in an intensive state by using the magnetism-insulating powder made of the Fe-Ni alloy materials, the ventilation micropores are formed, the aperture of each ventilation micropore is smaller than the particle size of the magnetism-insulating powder, on the basis of realizing air circulation, the magnetism-insulating powder is not easy to leak outwards, the outer end of the push block 907 is arranged in a water droplet shape, the left end and the right end of the connecting movable block 908 are fixedly connected with slide blocks, the inner wall of the suspension frame 700 and the outer end of the screening frame 100 are both provided with chutes which are connected in a sliding manner, and the movement of the connecting movable block 908 is more smooth and convenient through the arrangement of the slide blocks and the chutes, the friction influence is reduced, the release valve 9010 is in a gathering state when not being squeezed, the release valve 9010 is in an opening state after being squeezed, the cooling gel is not prone to flowing outwards through the release valve 9010 in the gathering state, the blocking effect is achieved, and the gathering state in the opening state after being squeezed can achieve flowing of the cooling gel, so that the cooling gel can be conveniently replenished.
The blowing mechanism 1000 comprises an elastic extrusion film 10001 fixedly connected with the inner wall of the ejection cylinder 803, the outer end of the elastic extrusion film 10001 is fixedly connected with a magnet sheet 10002, one end of the magnet block 906, which is close to the magnet sheet 10002, is repelled, the outer end of the ejection cylinder 803 is provided with a plurality of evenly distributed air injection holes, the inner wall of each air injection hole is fixedly connected with a movable ejection bottle nozzle 10003, after the magnetism-insulated capsule 905 expands, magnetism-insulated powder diffuses, the magnetic shielding of the magnet block 906 is cancelled, the repelled magnet sheet 10002 drives the elastic extrusion film 10001 to bend and extrude air in the ejection cylinder 803 to be ejected through the movable ejection bottle nozzle 10003, and raw material bacterial powder accumulated on the screen 500 is blown away, so that the blockage is not easy to occur, and the screening effect is enhanced.
In the invention, firstly, a sealing cover is opened, raw material bacterial powder is added on a screen mesh 500 through a feeding pipe 400, a swing motor 201 is driven to drive a screening hopper 300 and the screen mesh 500 to swing back and forth by means of a swing connecting rod 202, the raw material bacterial powder gathered on the screen mesh 500 is scattered, then in the swinging process, the screening hopper 300 drives an extrusion hemisphere 804 to extrude a stirring plate 802 back and forth to move so that the screening hopper 300 and the stirring plate 300 generate vibration, the vibration passes through an injection cylinder 803 to shake off the raw material bacterial powder remained on the inner wall of the screening hopper 300, the stirring plate 802 is extruded to drive a pressing rod 903 to push a piston 902 to blow air in an air injection cylinder 901 into a magnetism-insulating bag body 905 so that the air expands upwards to drive a pushing block 907 and a connecting movable block 908 to move upwards, the cooling gel in an extrusion storage ball bag 909 is supplemented into a circular pipe 1100 through a conduction pipe 1200, and the cooling gel consumed after gasification and heat absorption in the circular pipe 1100 can be supplemented, guarantee its stable heat dissipation, the expansion back of the utricule 905 of magnet insulation simultaneously, the powder diffusion of magnet insulation cancels the magnetic screen of magnet piece 906, repels magnet piece 10002 and drives the air in the crooked extrusion injection section of thick bamboo 803 of elasticity extrusion membrane 10001 and spout through sports type injection bottle mouth 10003, blows off the raw materials fungus powder of piling up on screen cloth 500, makes it difficult emergence jam, at last after the screening, opens dodge gate 600 and gets the raw materials fungus powder after the screening fast.
Example 1:
the probiotic composition with the function of reducing blood fat comprises the following components in parts by weight,
20 parts of enterococcus faecium powder, 20 parts of bacillus subtilis powder, 10 parts of bifidobacterium powder, 10 parts of lactobacillus acidophilus powder, 1 part of bacillus natto powder, 1 part of lactobacillus casei powder, 5 parts of lactobacillus salivarius powder, 1 part of bacillus powder, 10 parts of bacillus duchenius powder, 1 part of paracoccus powder, 1 part of other cladosporium powder, 10 parts of akmansonia muciniphilus powder, 10 parts of Lachnospiraceae NK4A136group bacteria powder, 15 parts of blautia bacteria powder and 10 parts of galactooligosaccharides.
Example 2:
the probiotic composition with the function of reducing blood fat comprises the following components in parts by weight,
30 parts of enterococcus faecium powder, 30 parts of bacillus subtilis powder, 22 parts of bifidobacterium powder, 15 parts of lactobacillus acidophilus powder, 10 parts of bacillus natto powder, 10 parts of lactobacillus casei powder, 10 parts of lactobacillus salivarius powder, 5 parts of lactobacillus powder, 15 parts of lactobacillus powder, 5 parts of paracoccus powder, 5 parts of corynebacterium bacteria powder, 15 parts of trichoderma bacteria powder, 15 parts of akkermanophilus powder, 15 parts of Lachnospiraceae NK4A136group bacteria powder, 25 parts of blautia bacteria powder and 15 parts of galactooligosaccharides.
Example 3:
the probiotic composition with the function of reducing blood fat comprises the following components in parts by weight,
22 parts of enterococcus faecium powder, 23 parts of bacillus subtilis powder, 13 parts of bifidobacterium powder, 12 parts of lactobacillus acidophilus powder, 3 parts of bacillus natto powder, 2 parts of lactobacillus casei powder, 6 parts of lactobacillus salivarius powder, 2 parts of lactobacillus powder, 12 parts of dorferi powder, 2 parts of paramylon powder, 2 parts of cladosporium powder, 11 parts of akkermanomyces muciniphila powder, 12 parts of Lachnospiraceae NK4A136group bacteria powder, 18 parts of blautidae bacteria powder and 12 parts of galactooligosaccharides.
Example 4:
the probiotic composition with the function of reducing blood fat comprises the following components in parts by weight,
27 parts of enterococcus faecium powder, 28 parts of bacillus subtilis powder, 20 parts of bifidobacterium powder, 14 parts of lactobacillus acidophilus powder, 7 parts of bacillus natto powder, 8 parts of lactobacillus casei powder, 9 parts of lactobacillus salivarius powder, 4 parts of lactobacillus powder, 14 parts of lactobacillus powder, 4 parts of paracoccus powder, 4 parts of other cladosporium powder, 14 parts of stickophilin akmansonia powder, 14 parts of Lachnospiraceae NK4A136group bacteria powder, 22 parts of blautia bacteria powder and 14 parts of galactooligosaccharides.
Example 5:
the probiotic composition with the function of reducing blood fat comprises the following components in parts by weight,
25 parts of enterococcus faecium powder, 25 parts of bacillus subtilis powder, 15 parts of bifidobacterium powder, 13 parts of lactobacillus acidophilus powder, 5 parts of bacillus natto powder, 5 parts of lactobacillus casei powder, 8 parts of lactobacillus salivarius powder, 3 parts of bacillus eubacterium powder, 13 parts of bacillus duchenii powder, 3 parts of paracoccus powder, 3 parts of other cladosporium powder, 12 parts of stickophilum akkermanensis powder, 13 parts of Lachnospiraceae NK4A136group bacteria powder, 20 parts of blautia bacteria powder and 13 parts of galactooligosaccharides.
Test animals and test methods:
1.1 animal models
Male C57 mice, 8 weeks old, were acclimatized for one week, and all mice were fed daily high-fat diet and mice were fed free diet. Mice were continuously given 60% high fat diet for at least 8 weeks and the mice were weighed weekly. 3 mice were bled at 4 weeks, 6 weeks, and 8 weeks, and sera were separated for lipid metabolism assay: TC, TG, LDL-C, HDL-C.
After the obesity model is successfully established, the obese mice are randomly divided into 3 groups of 8 mice, the tested drugs are continuously administered for 8 weeks, the mice are euthanized after 8 weeks, and sampling detection is carried out.
1.2 group settings, as shown in Table 1
Table 1: experimental group information table
Group of Number of Drug delivery intervention
B02 9 Collecting blood from three mice at 4 weeks, 6 weeks, and 8 weeks, respectively, and separating serum
A01 3 Feeding with common feed, collecting blood in 8 weeks, and separating serum
A02
8 Feeding with common feed, and intragastric irrigating with physiological saline 0.1ml/10g for 8 weeks after molding
B01 8 HFD + physiological saline (added with adjuvant) 0.1ml/10g for 8 weeks
C01
8 HFD + prebiotics (4g/kg/d), 8 weeks
C02
8 HFD + probiotic composition (bacterial powder 0.23g/30g body weight) for 8 weeks
C03
8 HFD + prebiotics + probiotic composition (4g/kg/d, bacterial powder 0.23g/30g body weight), 8 weeks
Note: a: a control group; b: a model group; c: test group
Second, experimental reagent material
2.1 test reagents, as shown in Table 2
Table 2: medicine information table
Figure BDA0003563826310000121
Figure BDA0003563826310000131
Note: the probiotic and prebiotic composition in example 5 of the invention is not powder and is ready for use
2.2 materials of the experiment
1ml syringe, electronic scale
Third, experimental results
In this experiment 49 mice of C57 were fed 60% caloric high fat diet and 13 mice of C57 were fed normal breeding diet. Experimental mice fed with 3 high-fat diets (group B02) were euthanized at 4, 6, and 8 weeks, respectively, and control mice fed with 3 normal diets (group a 01) were sacrificed at 8 weeks to determine whether an obesity model was established and to judge the time of initiation of the test drug intervention.
The test drug intervention was started at week 9 of high fat feeding for 7 weeks, at which time 3 samples were taken from each group and the remaining mice were administered for a further 1 week, and the experimental animals were euthanized at the experimental nodes.
3.1 establishing obesity model
The weight of the mice after the high-fat feeding for 8 weeks is obviously different from that of the mice fed with the common feed. In addition, by detecting lipid metabolism indexes, TG and TC are increased, and LDL-C/HDL-C are reduced, which indicates that the blood fat of the mice is increased after 8 weeks of high fat feeding. These results suggest that modeling of the hyperlipidemic obesity model was initially successful.
3.2 Effect of probiotic + prebiotic compositions of the invention on body weight in obese mice
The body weight of the mice fed with high fat is obviously different from that of the control group after 8 weeks, and is obviously higher than that of the control group. The administration intervention was started at week 9 and statistical analysis showed that the administration intervention did not show a significant weight loss effect at 7 weeks and did not show a significant weight loss effect at 8 weeks.
3.3 Effect of the probiotic + prebiotic composition of the invention on the blood lipid of obese mice
As shown in FIG. 7, serum was taken from 3 mice per group at 7 weeks of administration to examine the blood lipid 4 phase. The test drugs showed some lipid-lowering effect, and the TC, TG and LDL-C data of the test group showed a tendency to be down-regulated compared to the model group. As shown in fig. 8, the data of the administration index showed the same trend at 8 weeks of administration.
HDL-C high density lipoprotein, synthesized primarily in the liver, is an anti-atherosclerotic lipoprotein that transports cholesterol from extrahepatic tissues to the liver for metabolism. A higher HDL-C/LDL-C value indicates a better antilipemic effect.
Conclusion
The experiment proves that the obesity model is successfully constructed, and the weight of the obese mouse is obviously different from that of a control group by more than 20%. On the basis, the pharmacodynamic experiment of the tested medicine is carried out. The percent relative abundance of the final genus levels of the test group is shown in figure 9. The experimental result shows that the tested medicine has the function of reducing blood fat to a certain extent.
The foregoing is only a preferred embodiment of the present invention; the scope of the invention is not limited thereto. Any person skilled in the art should be able to cover the technical scope of the present invention by equivalent or modified solutions and modifications within the technical scope of the present invention.

Claims (9)

1. The probiotic composition with the function of reducing blood fat is characterized in that: comprises the following components in parts by weight,
20-30 parts of enterococcus faecium powder, 20-30 parts of bacillus subtilis powder, 10-22 parts of bifidobacterium powder, 10-15 parts of lactobacillus acidophilus powder, 1-10 parts of bacillus natto powder, 1-10 parts of lactobacillus casei powder, 5-10 parts of lactobacillus salivarius powder, 1-5 parts of eubacterium powder, 10-15 parts of lactobacillus ducreyi powder, 1-5 parts of paramylobacter powder, 1-5 parts of cladosporium powder, 10-15 parts of mucoprotein akkermanomyces powder, 10-15 parts of Lachnospiraceae NK4A136group bacteria powder, 15-25 parts of Braudauer bacteria powder and 10-15 parts of galactooligosaccharides.
2. The probiotic composition with hypolipidemic effect according to claim 1, characterized in that: comprises the following components in parts by weight,
22-27 parts of enterococcus faecium powder, 23-28 parts of bacillus subtilis powder, 13-20 parts of bifidobacterium powder, 12-14 parts of lactobacillus acidophilus powder, 3-7 parts of bacillus natto powder, 2-8 parts of lactobacillus casei powder, 6-9 parts of lactobacillus salivarius powder, 2-4 parts of eubacterium powder, 12-14 parts of lactobacillus ducreyi powder, 2-4 parts of paramylobacter powder, 2-4 parts of cladosporium powder, 11-14 parts of mucoprotein akkermanomyces powder, 12-14 parts of bacteria powder of Lachnospiraceae NK4A136group, 18-22 parts of blautia bacteria powder and 12-14 parts of galactooligosaccharides.
3. The preparation method of the probiotic composition with the function of reducing blood fat is characterized by comprising the following steps: comprises the following steps of (a) carrying out,
(S01) selecting a strain: selecting enterococcus faecium strains;
(S02) seed production: selecting a sterile environment, taking out the strain by using an inoculating needle, putting the strain into a triangular flask with a culture medium, sealing a bottle mouth, and putting the bottle mouth into an incubator, wherein the temperature of the incubator is 35-37 ℃, and performing static culture for 20-30 h;
(S03) sterilization: sterilizing the first fermentation tank in vacuum, then putting the first fermentation tank into a culture medium for sterilization, wherein the sterilization temperature is more than 150 ℃, the pressure in the first fermentation tank is 0.15-0.25 MPa, the sterilization lasts for 25-35 min, then the temperature in the first fermentation tank is reduced to 35-37 ℃ by cooling water, and the pressure in the first fermentation tank is reduced to 0.01-0.03 MPa;
(S04) inoculation: firstly, putting seeds in an incubator into a sterile room for sampling microscopic examination, inoculating, unscrewing a sealing cover of an inoculating port, introducing a trace amount of sterile air into a first fermentation tank, ensuring that the pressure in the tank is not zero, placing an inoculating flame ring in the inoculating port, igniting the flame ring, completely opening the inoculating cover, then placing a triangular flask above the flame ring, opening the triangular flask, pouring the seeds into the first fermentation tank, screwing the inoculating cover after the pressure is over, introducing the sterile air into the first fermentation tank, stopping when the pressure in the first fermentation tank reaches 0.05-0.09 MPa, maintaining the pressure, keeping the temperature at 35-37 ℃ and the pressure at 0.05-0.09 MPa, adjusting the stirring rotation speed to 40-60 r/min, and culturing for 20-30 h;
(S05) transferring seeds: performing the step (S02) on the second fermentation tank, and then inoculating the strain in the first fermentation tankTransferring the mixture into a second fermentation tank with a prepared culture medium through a sterilized pipeline, keeping the temperature at 35-37 ℃ and the pressure at 0.05-0.09 MPa, adjusting the stirring speed to 40-60 r/min, and culturing for 20-30 h to ensure that the density of strains in the second fermentation tank is 6 multiplied by 108～12×108cfu/g；
(S06) centrifuging: enabling the bacterial liquid to pass through a centrifugal machine, enabling the centrifugal machine to rotate clockwise at the rotating speed of 12000 r/min-17000 r/min, carrying out bacterial liquid separation, and taking out bacterial sludge after the bacterial liquid separation is finished;
(S07) lyophilization: placing the bacterial sludge in a plate layer of a freeze dryer, performing freeze drying operation, and automatically vacuumizing when the temperature of a cold trap of the freeze dryer is-45 ℃ to-55 ℃;
(S08) pulverizing: crushing the freeze-dried bacterial sludge to prepare enterococcus faecium bacterial powder;
(S09) preparing Bacillus subtilis powder, Bifidobacterium powder, Lactobacillus acidophilus powder, Bacillus natto powder, Lactobacillus casei powder, Lactobacillus salivarius powder, Bacillus mycoides powder, Bacillus duchensis powder, Bacillus subtilis powder, Sclerotinia bacteria powder, Ackermanomyces muciniphila powder, Lachnospiraceae NK4A136group powder and Blauteria powder: respectively repeating the steps (S02) to (S08) with bacillus subtilis, bifidobacterium, lactobacillus acidophilus, bacillus natto, lactobacillus casei, lactobacillus salivarius, eubacterium, duchenium, paracoccus, cladosporium, akmansia muciniphila, Lachnospiraceae NK4A136group bacteria and blautiella to obtain bacillus subtilis powder, bifidobacterium powder, lactobacillus acidophilus powder, bacillus natto powder, lactobacillus casei powder, lactobacillus salivarius powder, bacillus powder, duchenium powder, bacillus subtilis powder, bifidobacterium powder, another mycobacterium powder, akmansonium muciniphilus powder, Lachnospiraceae NK4A136group bacteria powder and blautiella powder;
(S10) sieving: screening enterococcus faecium powder, bacillus subtilis powder, bifidobacterium powder, lactobacillus acidophilus powder, bacillus natto powder, lactobacillus casei powder, lactobacillus salivarius powder, bacillus mycoides powder, lactobacillus duchenii powder, bacillus subtilis powder, mycobacterium powder, other-cladium powder, adhesive protein akmansonium powder, Lachnospiraceae NK4A136group powder, blautia powder and galacto-oligosaccharide by a screening device respectively;
(S11) manufacturing: under the aseptic condition, the screened enterococcus faecium powder, bacillus subtilis powder, bifidobacterium powder, lactobacillus acidophilus powder, bacillus natto powder, lactobacillus casei powder, lactobacillus salivarius powder, bacillus eubacterium powder, lactobacillus dorferi powder, bacillus paramterium powder, other-cladia bacteria powder, mucinophilin akmanomyces powder, Lachnospiraceae NK4A136group bacteria powder, Blattella bacteria powder and galactooligosaccharides are prepared and uniformly mixed according to the weight proportion to prepare the probiotic composition with the function of reducing blood fat.
4. The method for preparing probiotic composition with hypolipidemic effect according to claim 3, wherein the method comprises the following steps: the screening device comprises a screening frame (100), the screening hopper (300) is connected to the inside of the screening frame (100) in a rotating mode, a screen (500) is fixedly connected to the lower end of the screening hopper (300), a driving mechanism (200) is arranged between the screening hopper (300) and the screening frame (100), an inlet pipe (400) is embedded into each of the left end and the right end of the screening frame (100), a sealing cover is arranged at each of the outer ends of the inlet pipes (400), a shifting transmission mechanism (800) is installed on the inner walls of the left end and the right end of the screening frame (100), an air blowing mechanism (1000) is embedded into each of the left end and the right end of the screening hopper (300), the transmission mechanism (800) is located on the outer side of the air blowing mechanism (1000), a suspension connection frame (700) is fixedly connected to each of the left end and the right end of the screening frame (100), an annular pipe (1100) is fixedly connected to each of the upper end of the screening frame (100), and a conduction pipe (1200) is fixedly connected to each of the suspension frame (700) and the annular pipe (1100), the conduction pipe (1200) is linked together with the inside of suspension frame (700) and toroidal tube (1100) respectively, be equipped with extrusion complementary unit (900) between suspension frame (700) and conduction pipe (1200), the chisel has the material taking mouth in the outer end of screening frame (100), and the material taking mouth internal rotation is connected with dodge gate (600).
5. The method for preparing probiotic composition with hypolipidemic effect of claim 4, wherein the method comprises the following steps: actuating mechanism (200) are including installing swing motor (201) on top in screening frame (100), fixedly connected with swing joint pole (202) between the inner wall of screening fill (300), the upper end of swing joint pole (202) flushes with the upper end of screening fill (300) mutually, the power take off end of swing motor (201) and the upper end fixed connection of swing joint pole (202).
6. The method for preparing probiotic composition with hypolipidemic effect of claim 4, wherein the method comprises the following steps: stir transfer mechanism (800) including with screening frame (100) inner wall fixed connection's a pair of straight board (801) of being connected, it is a pair of it is connected with stirring board (802) to connect to rotate between straight board (801), the outer end of screening fill (300) is inlayed and is equipped with injection cylinder (803), the outer end fixedly connected with extrusion hemisphere (804) of injection cylinder (803), extrusion hemisphere (804) contact with stirring board (802).
7. The method for preparing probiotic composition with hypolipidemic effect according to claim 6, wherein the probiotic composition comprises the following components: the extrusion supplementing mechanism (900) comprises an air injection cylinder (901) embedded on the outer end of the screening frame (100), a piston (902) is connected inside the air injection cylinder (901) in a sliding manner, a pressing rod (903) is fixedly connected to the outer end of the piston (902), a through hole is drilled in the inner wall of the air injection cylinder (901), the pressing rod (903) penetrates through the through hole to be connected with the poking plate (802) in a rotating manner, a magnetism insulation capsule (905) is fixedly connected between the suspension frame (700) and the screening frame (100), a magnet block (906) is arranged inside the magnetism insulation capsule (905), magnetism insulation powder is filled inside the magnetism insulation capsule (905), the air injection cylinder (901) is fixedly connected with the magnetism insulation capsule (905), the air injection cylinder (901) is communicated with the inside of the magnetism insulation capsule (905), a ventilation spacer (904) is fixedly connected to the inner wall of the air injection cylinder (901), and a pushing block (907) is fixedly connected to the upper end of the magnetism insulation capsule (905), a connecting movable block (908) is connected between the suspension frame (700) and the screening frame (100) in a sliding way, the connection movable block (908) is fixedly connected with the pushing block (907), the inner top end of the suspension frame (700) is fixedly connected with a storage balloon (909), the storage balloon (909) is fixedly connected with the connecting movable block (908), the conduction pipe (1200) penetrates through the upper end of the suspension frame (700), the conduction pipe (1200) is fixedly connected with the storage balloon (909), the conduction pipe (1200) is communicated with the interior of the storage balloon (909), the storage balloon (909), the conduction tube (1200) and the annular tube (1100) are all internally provided with cooling gel, the inside fixedly connected with release valve (9010) of conduction pipe (1200), the initial state of release valve (9010) is the state of drawing in, the upper end of screening frame (100) is equipped with the diamond powder layer.
8. The method for preparing probiotic composition with hypolipidemic effect according to claim 7, wherein the probiotic composition comprises: the magnetic isolation powder is made of Fe-Ni alloy materials, the Ni content in the magnetic isolation powder is 80%, the outer end of the air-permeable partition (904) is provided with a plurality of air-permeable micropores which are uniformly distributed in a chiseling mode, and the pore diameter of each air-permeable micropore is smaller than the particle size of the magnetic isolation powder; the outer end of the pushing block (907) is arranged in a water-drop shape, the left end and the right end of the connecting movable block (908) are fixedly connected with sliding blocks, sliding grooves are formed in the inner wall of the suspension hanging frame (700) and the outer end of the screening frame (100), and the sliding blocks are connected with the sliding grooves in a sliding mode; the release valve (9010) is in a gathered state when not squeezed, and the release valve (9010) is in an open state after being squeezed.
9. The method for preparing probiotic composition with hypolipidemic effect of claim 7, wherein the method comprises the following steps: the blowing mechanism (1000) comprises an elastic extrusion film (10001) fixedly connected with the inner wall of the ejection cylinder (803), the outer end of the elastic extrusion film (10001) is fixedly connected with a magnet piece (10002), one end, close to each other, of the magnet piece (906) is repelled with one end of the magnet piece (10002), the outer end of the ejection cylinder (803) is provided with a plurality of uniformly distributed air injection holes, and the inner wall of each air injection hole is fixedly connected with a movable ejection bottle nozzle (10003).
CN202210303538.4A 2022-03-24 2022-03-24 Probiotics composition with blood fat reducing function, preparation method and equipment Pending CN114634892A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210303538.4A CN114634892A (en) 2022-03-24 2022-03-24 Probiotics composition with blood fat reducing function, preparation method and equipment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210303538.4A CN114634892A (en) 2022-03-24 2022-03-24 Probiotics composition with blood fat reducing function, preparation method and equipment

Publications (1)

Publication Number Publication Date
CN114634892A true CN114634892A (en) 2022-06-17

Family

ID=81949633

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210303538.4A Pending CN114634892A (en) 2022-03-24 2022-03-24 Probiotics composition with blood fat reducing function, preparation method and equipment

Country Status (1)

Country Link
CN (1) CN114634892A (en)

Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101511377A (en) * 2006-08-21 2009-08-19 卡尔皮斯株式会社 Lipid-metabolism-ameliorating agent
CN102028713A (en) * 2010-12-12 2011-04-27 夏学德 Probiotic preparation used for reducing serum cholesterol and preparation method thereof
CN104413334A (en) * 2013-08-30 2015-03-18 深圳华大基因科技有限公司 Edible composition as well as preparation method and application thereof
CN104415060A (en) * 2013-08-30 2015-03-18 深圳华大基因科技有限公司 Edible composition as well as preparation method and application thereof
CN107496463A (en) * 2017-08-16 2017-12-22 山西亿科宏泰生物科技有限公司 A kind of probiotics medicine of lowering blood pressure and blood fat and preparation method thereof
CN206974288U (en) * 2017-07-28 2018-02-06 浏阳市鸿安机械制造有限公司 Medicine production line is wrapped up in fireworks granulation
CN207351115U (en) * 2017-06-01 2018-05-11 骆玲晓 A kind of heated air circulation type material screens drying device
CN207680567U (en) * 2017-12-21 2018-08-03 江西舒美特药业有限公司 A kind of particle sizing device of probiotics chewable tablets
CN109259243A (en) * 2018-09-26 2019-01-25 广州普维君健药业有限公司 Composition of lower hyperlipidemia, hypertension, hyperglycemia and its preparation method and application
CN208786930U (en) * 2018-08-03 2019-04-26 安徽九州金诺药业股份有限公司 A kind of packaged type vibrating dust removing screening all-in-one machine for the prepared slices of Chinese crude drugs
CN110075226A (en) * 2019-04-10 2019-08-02 上海汉康豆类食品有限公司 It is a kind of can be with the probiotic composition of reducing blood lipid
CN110693916A (en) * 2019-09-23 2020-01-17 北京量化健康科技有限公司 Application of blautia in preparation of product for enhancing efficacy of hypolipidemic drug for treating hyperlipidemia
CN211330264U (en) * 2019-12-11 2020-08-25 福州东星生物技术有限公司 Multi-stage edible mushroom screening device
CN111603488A (en) * 2012-11-19 2020-09-01 卢万天主教大学 Use of akkermansia for the treatment of metabolic disorders
CN111686133A (en) * 2020-07-24 2020-09-22 江南大学 Application of bacterium dorferi in preventing and improving obesity and related diseases
CN111728986A (en) * 2020-07-29 2020-10-02 慕恩（广州）生物科技有限公司 Probiotic composition, application thereof and probiotic product
JP2021029244A (en) * 2019-08-27 2021-03-01 呉剛 Medicine drug substance screening device
CN213161896U (en) * 2020-06-28 2021-05-11 湖南君泰生物科技股份有限公司 Feed raw and other materials sieving mechanism
CN113058835A (en) * 2021-04-06 2021-07-02 李晓龙 Multistage screening system of probiotic capsule production preparation

Patent Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101511377A (en) * 2006-08-21 2009-08-19 卡尔皮斯株式会社 Lipid-metabolism-ameliorating agent
CN102028713A (en) * 2010-12-12 2011-04-27 夏学德 Probiotic preparation used for reducing serum cholesterol and preparation method thereof
CN111603488A (en) * 2012-11-19 2020-09-01 卢万天主教大学 Use of akkermansia for the treatment of metabolic disorders
CN104413334A (en) * 2013-08-30 2015-03-18 深圳华大基因科技有限公司 Edible composition as well as preparation method and application thereof
CN104415060A (en) * 2013-08-30 2015-03-18 深圳华大基因科技有限公司 Edible composition as well as preparation method and application thereof
CN207351115U (en) * 2017-06-01 2018-05-11 骆玲晓 A kind of heated air circulation type material screens drying device
CN206974288U (en) * 2017-07-28 2018-02-06 浏阳市鸿安机械制造有限公司 Medicine production line is wrapped up in fireworks granulation
CN107496463A (en) * 2017-08-16 2017-12-22 山西亿科宏泰生物科技有限公司 A kind of probiotics medicine of lowering blood pressure and blood fat and preparation method thereof
CN207680567U (en) * 2017-12-21 2018-08-03 江西舒美特药业有限公司 A kind of particle sizing device of probiotics chewable tablets
CN208786930U (en) * 2018-08-03 2019-04-26 安徽九州金诺药业股份有限公司 A kind of packaged type vibrating dust removing screening all-in-one machine for the prepared slices of Chinese crude drugs
CN109259243A (en) * 2018-09-26 2019-01-25 广州普维君健药业有限公司 Composition of lower hyperlipidemia, hypertension, hyperglycemia and its preparation method and application
CN110075226A (en) * 2019-04-10 2019-08-02 上海汉康豆类食品有限公司 It is a kind of can be with the probiotic composition of reducing blood lipid
JP2021029244A (en) * 2019-08-27 2021-03-01 呉剛 Medicine drug substance screening device
CN110693916A (en) * 2019-09-23 2020-01-17 北京量化健康科技有限公司 Application of blautia in preparation of product for enhancing efficacy of hypolipidemic drug for treating hyperlipidemia
CN211330264U (en) * 2019-12-11 2020-08-25 福州东星生物技术有限公司 Multi-stage edible mushroom screening device
CN213161896U (en) * 2020-06-28 2021-05-11 湖南君泰生物科技股份有限公司 Feed raw and other materials sieving mechanism
CN111686133A (en) * 2020-07-24 2020-09-22 江南大学 Application of bacterium dorferi in preventing and improving obesity and related diseases
CN111728986A (en) * 2020-07-29 2020-10-02 慕恩（广州）生物科技有限公司 Probiotic composition, application thereof and probiotic product
CN113058835A (en) * 2021-04-06 2021-07-02 李晓龙 Multistage screening system of probiotic capsule production preparation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MENQ-RONG WU等: "A potential probiotic- Lachnospiraceae NK4A136 group: Evidence from the restoration of the dietary pattern from a high-fat diet", 《RESEARCH SQUARE》, pages 1 - 24 *
刘碧凡等: "脂肪酸代谢与肠道微生物定植的相互作用", 《动物营养学报》, vol. 32, no. 4, pages 1536 - 1543 *

Similar Documents

Publication Publication Date Title
CN108004189B (en) Composite probiotic lactic acid bacteria powder and preparation method and application thereof
EP1478246B1 (en) Dietetic and/or pharmaceutical compositions for human and/or animal use based on probiotic microbial preparations
CN1153575C (en) Pharmaceutical preparation comprising lactobacillus casei phamnosus
KR101493302B1 (en) Processing of natural polysaccharides by selected non-pathogenic microorganisms and methods of making and using the same
CN101366734A (en) Synbiotics medicament composition
CN108782758B (en) Fermented synbiotic goat milk powder and preparation method thereof
CN100342005C (en) Process for preparing high actived alctic acid bacteria product
JP2009189374A (en) New galactooligosaccharide composition and method for preparing the same
CN103283975A (en) A method of using spray drying for preparing probiotics micro-capsules
CN103997899A (en) Probiotic compositions and methods
CN104531549B (en) A kind of lactobacillus fermenti Lactobacillus fermentum strain Zhao and application thereof of adjustable intestinal movement, Constipation
CN104430847B (en) Lactobacillus fermenti Lactobacillus fermentum Lee working stock cultures products and its Constipation health purpose
CN104381440B (en) Lactobacillus fermenti Lactobacillus fermentum strain Lee working stock cultures products and its Constipation health purpose
CN107164274A (en) A kind of lactic acid bacteria composite fungicide and its preparation method and application
CN107397042A (en) A kind of composite type animal enteron aisle regulation preparation and preparation method thereof
CN113005067B (en) Multifunctional composite probiotic preparation and preparation method thereof
CN110710690A (en) Prebiotic composition for rapid proliferation of beneficial intestinal bacteria
CN111000246A (en) Probiotic dietary fiber composition for assisting in reducing triglyceride, application thereof and health-care product
CN112218646A (en) Composition and application thereof
CN114921363A (en) Composite probiotics for inhibiting fat accumulation and application thereof
CN1225551C (en) Liquid-solid combined fermentation process of probiotics by using bifidobacteria as main component
CN1089567C (en) Composite microecological health-care food and its preparing process
CN113424965A (en) Microecological preparation more suitable for yellow population
CN114634892A (en) Probiotics composition with blood fat reducing function, preparation method and equipment
EP1997880A1 (en) Breast milk bifidobacteria, compositions thereof, their use and a novel culture media to obtain them

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination